immunotherapy Archives - BJBMS Viewpoints

September 19, 2020

Latest posts

[ September 18, 2020 ] Pharmacogenomics biomarkers for personalized methadone maintenance treatment Author Summary
[ September 16, 2020 ] BJBMS welcomes the New Editor: Dr. Zhe-Sheng (Jason) Chen News
[ September 8, 2020 ] The cytoreductive nephrectomy in patients with renal cell carcinoma and liver metastasis Author Summary
[ August 31, 2020 ] New polymorphisms associated with gastric cancer Author Summary
[ August 25, 2020 ] Clinical applications of eggshell-derived hydroxyapatite in bone regeneration Author Summary

Positive PD-L1 (SP142 clone) IHC staining (2+, 85%) of a MSI-H colorectal tumor with concurrent BRAF V600E mutation; image taken at 20x magnification (Left image); Positive PD-1 (Cell Marque) IHC staining; image taken at 40x magnification (Right image).

Microsatellite instability status predicts response to anti-PD-L1 therapy regardless the histotype

July 22, 2017 0

Le et al. recently reported (Science 10.1126/science.aan6733 (2017); (ClinicalTrials.gov number, NCT01876511) on the success of immune checkpoint blockade with anti-PD-1 antibodies in the patients whose cancers exhibited microsatellite instability-high (MSI-H) status. The study included 12 […]

Recent advances in cancer immunotherapy based in immune checkpoint inhibitors

June 9, 2017 0

Targeted therapy based on the immune checkpoint inhibitors (Anti-PD1/PD-L1) has revolutionized cancer treatment and outcome of several solid and hematologic malignancies, including non-small cell lung carcinoma (NSCLC), metastatic renal cell carcinoma, metastatic malignant melanoma, advanced/metastatic […]

BJBMS Viewpoints

Science in plain words

immunotherapy

Microsatellite instability status predicts response to anti-PD-L1 therapy regardless the histotype

Recent advances in cancer immunotherapy based in immune checkpoint inhibitors

What matters the most when choosing the journal to submit your article?